SK1282003A3 - Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma - Google Patents
Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma Download PDFInfo
- Publication number
- SK1282003A3 SK1282003A3 SK128-2003A SK1282003A SK1282003A3 SK 1282003 A3 SK1282003 A3 SK 1282003A3 SK 1282003 A SK1282003 A SK 1282003A SK 1282003 A3 SK1282003 A3 SK 1282003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- fraction
- tumor
- treatment
- lipid
- blood
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 82
- 238000011282 treatment Methods 0.000 title claims abstract description 55
- 210000002381 plasma Anatomy 0.000 title claims abstract description 45
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 4
- 238000000034 method Methods 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title description 24
- 238000003745 diagnosis Methods 0.000 title description 5
- 150000002632 lipids Chemical class 0.000 title 1
- 210000004369 blood Anatomy 0.000 claims abstract description 41
- 239000008280 blood Substances 0.000 claims abstract description 41
- 241000283690 Bos taurus Species 0.000 claims abstract description 33
- 239000004094 surface-active agent Substances 0.000 claims abstract description 16
- 239000003960 organic solvent Substances 0.000 claims abstract description 14
- 238000005119 centrifugation Methods 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 4
- 238000001962 electrophoresis Methods 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 11
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000005995 Aluminium silicate Substances 0.000 claims description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 5
- 235000012211 aluminium silicate Nutrition 0.000 claims description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical group O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000011581 secondary neoplasm Diseases 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 5
- 241000283086 Equidae Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 56
- 230000004083 survival effect Effects 0.000 description 46
- 238000002474 experimental method Methods 0.000 description 42
- 241001465754 Metazoa Species 0.000 description 33
- 239000000306 component Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 239000013641 positive control Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 230000006872 improvement Effects 0.000 description 11
- 238000002513 implantation Methods 0.000 description 10
- 206010000830 Acute leukaemia Diseases 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- 102000004008 5'-Nucleotidase Human genes 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 6
- 230000001133 acceleration Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000005741 malignant process Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000010722 N-Glycosyl Hydrolases Human genes 0.000 description 2
- 108010063372 N-Glycosyl Hydrolases Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 241000306001 Cetartiodactyla Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 108010002712 deoxyribonuclease II Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 108010048527 glycerol-2-phosphatase Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0002597A HUP0002597A2 (hu) | 2000-07-10 | 2000-07-10 | Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására |
| PCT/HU2001/000078 WO2002007739A2 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK1282003A3 true SK1282003A3 (en) | 2003-08-05 |
Family
ID=89978459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK128-2003A SK1282003A3 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040253317A1 (ru) |
| EP (1) | EP1333844A2 (ru) |
| JP (1) | JP2004504353A (ru) |
| KR (1) | KR20030016392A (ru) |
| CN (1) | CN1477965A (ru) |
| AU (1) | AU2001277630A1 (ru) |
| BG (1) | BG107547A (ru) |
| BR (1) | BR0112866A2 (ru) |
| CA (1) | CA2415862A1 (ru) |
| EA (1) | EA005415B1 (ru) |
| HR (1) | HRP20030098A2 (ru) |
| HU (1) | HUP0002597A2 (ru) |
| IL (1) | IL153867A0 (ru) |
| MX (1) | MXPA03000342A (ru) |
| PL (1) | PL361049A1 (ru) |
| SK (1) | SK1282003A3 (ru) |
| WO (1) | WO2002007739A2 (ru) |
| YU (1) | YU9903A (ru) |
| ZA (1) | ZA200300675B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0200172A2 (hu) | 2002-01-15 | 2003-11-28 | András Bertha | Eljárás tumorellenes hatóanyag kinyerésére |
| GB2405540B (en) * | 2003-08-27 | 2006-05-10 | Ron Shu-Yuen Hui | Apparatus and method for providing dimming control of lamps and electrical lighting systems |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB791142A (en) * | 1954-09-22 | 1958-02-26 | Atsuwo Ushiyama | A process for preparing antibiotic substance from special bacterium in human blood plasma and earth |
| GB834256A (en) * | 1955-08-18 | 1960-05-04 | Olin Mathieson | Therapeutic bone mixture |
| US3083194A (en) * | 1959-05-18 | 1963-03-26 | Thies Karl | Montmorillonite adsorption of fibrin from bovine blood plasma |
| JPS5357191A (en) * | 1976-11-04 | 1978-05-24 | Asahi Chem Ind Co Ltd | Activated carbon for adsorption of toxin in serum |
| NL9001087A (nl) * | 1990-05-07 | 1991-12-02 | Harimex Ligos Bv | Werkwijze voor het zuiveren van bloedplasma. |
| RO111332B1 (ro) * | 1991-06-17 | 1996-09-30 | Inst De Cercetari Chimico Farm | Procedeu de obținere a unui produs hepatoprotector |
| HUP9900045A3 (en) * | 1999-01-08 | 2001-02-28 | Martyn Robertne Goeroeg Jolan | Improved leukaemic blood-based product and their use in therapy |
-
2000
- 2000-07-10 HU HU0002597A patent/HUP0002597A2/hu unknown
-
2001
- 2001-07-10 SK SK128-2003A patent/SK1282003A3/sk unknown
- 2001-07-10 WO PCT/HU2001/000078 patent/WO2002007739A2/en not_active Application Discontinuation
- 2001-07-10 US US10/332,440 patent/US20040253317A1/en not_active Abandoned
- 2001-07-10 JP JP2002513472A patent/JP2004504353A/ja active Pending
- 2001-07-10 KR KR10-2003-7000393A patent/KR20030016392A/ko not_active Application Discontinuation
- 2001-07-10 EA EA200300133A patent/EA005415B1/ru not_active IP Right Cessation
- 2001-07-10 PL PL01361049A patent/PL361049A1/xx unknown
- 2001-07-10 IL IL15386701A patent/IL153867A0/xx unknown
- 2001-07-10 EP EP01955468A patent/EP1333844A2/en not_active Withdrawn
- 2001-07-10 CN CNA018139744A patent/CN1477965A/zh active Pending
- 2001-07-10 BR BRPI0112866 patent/BR0112866A2/pt not_active Application Discontinuation
- 2001-07-10 AU AU2001277630A patent/AU2001277630A1/en not_active Abandoned
- 2001-07-10 MX MXPA03000342A patent/MXPA03000342A/es unknown
- 2001-07-10 YU YU9903A patent/YU9903A/sh unknown
- 2001-07-10 CA CA002415862A patent/CA2415862A1/en not_active Abandoned
-
2003
- 2003-01-24 ZA ZA200300675A patent/ZA200300675B/xx unknown
- 2003-02-10 HR HR20030098A patent/HRP20030098A2/hr not_active Application Discontinuation
- 2003-02-10 BG BG107547A patent/BG107547A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2415862A1 (en) | 2002-01-31 |
| US20040253317A1 (en) | 2004-12-16 |
| MXPA03000342A (es) | 2004-12-13 |
| IL153867A0 (en) | 2003-07-31 |
| PL361049A1 (en) | 2004-09-20 |
| HRP20030098A2 (en) | 2004-08-31 |
| HU0002597D0 (en) | 2000-09-28 |
| ZA200300675B (en) | 2004-02-19 |
| WO2002007739A3 (en) | 2002-10-10 |
| EP1333844A2 (en) | 2003-08-13 |
| JP2004504353A (ja) | 2004-02-12 |
| BG107547A (bg) | 2004-01-30 |
| WO2002007739A2 (en) | 2002-01-31 |
| YU9903A (sh) | 2006-05-25 |
| AU2001277630A1 (en) | 2002-02-05 |
| HUP0002597A2 (hu) | 2003-01-28 |
| CN1477965A (zh) | 2004-02-25 |
| EA200300133A1 (ru) | 2003-06-26 |
| WO2002007739A9 (en) | 2003-10-16 |
| KR20030016392A (ko) | 2003-02-26 |
| BR0112866A2 (ru) | 2009-12-08 |
| EA005415B1 (ru) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | Natural killer cells in mice treated with 89strontium: normal target-binding cell numbers but inability to kill even after interferon administration | |
| JPH01124382A (ja) | 導入抗原タンパク質を有する動物由来細胞 | |
| AU2007305076A1 (en) | Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods | |
| JPS63146833A (ja) | 後生的なグリコシル化最終産物を除去する為の方法及び薬剤 | |
| WO2007087825A1 (en) | Use of a combination of ethanolic rosa sp . , urtica dioica and tanacetum vulgare extracts, further comprising selenium and urea and having been exposed to a pulsed electromagnetic field, for the preparation of a medicament for immunostimulation and/or treatment of hiv infections | |
| Weiden et al. | Immune reactivity in dogs with spontaneous malignancy | |
| SK1282003A3 (en) | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma | |
| EP1547615B1 (en) | Remedy | |
| US20170258862A1 (en) | Compositions for the treatment of age related disorders | |
| JPS59163323A (ja) | 動脈硬化性疾患防止剤 | |
| JP3778366B2 (ja) | 細胞成長調節因子 | |
| De Carvalho | Prodromal Dysimmunity in Cancer: Pathophysiology of Pre-and Perineoplastic Immune Deficiency Disorders that May Represent Syndromes of Transition from Dysimmunity to Cancer | |
| EP0650727A1 (en) | Use of hydroxychloroquine for treatment of graft-versus-host disease | |
| Berman et al. | Resistance to alkylating agents and tumour differentiation in xenografts of small cell lung cancer | |
| Dicke et al. | Transplantation of haemopoietic stem cell (HSC) concentrates for treatment of immune deficiency disease | |
| Abutu et al. | Regulatory activity of ethanol leaves extract of Moringa Oleifera on benzene induced leukemia in Wister Rat using TNF-α analysis | |
| JP3040699B2 (ja) | 毒性軽減剤 | |
| Abousleiman | Activation of Murine Dendritic Cells Through STING Pathway Interactions with Glycated Chitosan | |
| TW202108170A (zh) | 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法 | |
| Okunewick et al. | Rauscher leukemia as a model for studies of marrow transplantation therapy: Results using syngeneic, allogeneic and hybrid donors | |
| RU2304978C2 (ru) | Средство тканеспецифического регулирования митохондриальных процессов и его применение при лечении заболеваний (варианты) | |
| JP2016501260A (ja) | マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーＰＰＩ−Ｇ４−ＤＳ−Ｍａｌ−ＩＩＩの使用 | |
| MANSON et al. | THE INDUCTION OF ALLOGRAFT IMMUNITY IN VITRO | |
| Walton | Subcellular Injury: Ultrastructural Changes Induced in Cultured Cells by Metabolic Inhibitors and Other Agents | |
| Wolters | Cellular and genetic requirements for graft-versus-host reactivity |